Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: Results from a multicenter study

Cancer

Volumn 116, Issue 1, 2010, Pages 106-114

  Kahl, Brad S ^a   Bartlett, Nancy L ^b   Leonard, John P ^c   Chen, Ling ^d   Ganjoo, Kristen ^e   Williams, Michael E ^f   Czuczman, Myron S ^g   Robinson, K Sue ^h   Joyce, Robin ⁱ   Van Der Jagt, Richard H ^j   Cheson, Bruce D ^k  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d CEPHALON INC   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

^g ROSWELL PARK CANCER INSTITUTE   (United States)

^h QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

ⁱ BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^j UNIVERSITY OF OTTAWA   (Canada)

^k GEORGETOWN UNIVERSITY HOSPITAL   (United States)

more..

Author keywords

B cell lymphoma; Bendamustine; Clinical trial; Non Hodgkin lymphoma; Rituximab refractory

Indexed keywords

BENDAMUSTINE; DEXAMETHASONE; FLUDARABINE; MITOXANTRONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TOSITUMOMAB I 131;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; B CELL LYMPHOMA; BACKACHE; CANCER CHEMOTHERAPY; CARDIOPULMONARY ARREST; CHILL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; CONSTIPATION; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLICULAR LYMPHOMA; HEADACHE; HISTOLOGY; HUMAN; HYPERSENSITIVITY REACTION; HYPOTENSION; INFECTION; LEUKOPENIA; LOW DRUG DOSE; LUNG HEMORRHAGE; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MALE; MARGINAL ZONE LYMPHOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYCOBACTERIOSIS; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RESPIRATORY FAILURE; SEPSIS; SEPTIC SHOCK; SHOULDER PAIN; SINUSITIS; STOMATITIS; SWELLING; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS; TUMOR LYSIS SYNDROME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NITROGEN MUSTARD COMPOUNDS; RETREATMENT;

EID: 74549225036     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24714     Document Type: Article

References (29)

1. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417-1423.
2. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725-3732.
3. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25:1986-1992.
4. Foussard C, Mounier N, Van Hoof A, et al. Update of the FL2000 randomized trial combining rituximab to CHVP-interferon in follicular lymphoma patients [abstract]. J Clin Oncol. 2006;18S(June 20 suppl):424. Abstract 7508.
5. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Non-Hodgkin's Lymphomas. Version 3.2008. 04/10/08. Available at: http://www.nccn.org/professionals/physician-gls/PDF/nhl.pdf Accessed January 13, 2009.
6. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:3262-3269.
7. Horning SJ, Younes A, Jain V, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol. 2005;23:712-719.
8. Friedberg JW, Huang J, Dillon H, et al. National Lympho-Care Study Investigators. Initial therapeutic strategy in follicular lymphoma (FL): an analysis from the National Lymphocare Study (NLCS) [abstract]. J Clin Oncol. 2006;18S(June 20 suppl):428. Abstract 7527.
9. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008;14:309-317.
10. Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs. 1996;7:415-421.
11. Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anticancer Drugs. 2001;12:725-729.
12. Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. J Cancer Res Clin Oncol. 2002;128:603-609.
13. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:3383-3389.
14. Weide R, Hess G, Koppler H, et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma. 2007;48:1299-1306.
15. Herold M, Schulze A, Niederwieser D, et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO £19). J Cancer Res Clin Oncol. 2006;132:105-112.
16. Koenigsmann M, Knauf W, Herold M, et al. Fludarabine and bendamustine in refractory and relapsed indolent lymphoma - a multicenter phase I/II trial of the East German Society of Hematology and Oncology (OSHO). Leuk Lymphoma. 2004;45:1821-1827.
17. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol. 2008;26:204-210.
18. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244-1244.
19. National Cancer Institute. Common Terminology Criteria for Adverse Events, version 3.0 (CTCAE). Published August 9, 2006. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3. pdf Accessed January 13, 2009.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457-481.
21. Czuczman MS, Olejniczak S, Gowda A, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res. 2008;14:1561-1570.
22. Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clin Cancer Res. 2008;14:1550-1560.
23. Wade JC. Viral infections in patients with hematological malignancies. Hematology Am Soc Hematol Educ Program. 2006:368-374.
24. Bennett JM, Kaminski MS, Leonard JP, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood. 2005;105:4576-4582.
25. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol. 2003;21:897-906.
26. McLaughlin P, Estey E, Glassman A, et al. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood. 2005;105:4573-4575.
27. Czuczman MS, Emmanouilides C, Darif M, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol. 2007;25:4285-4292.
28. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:4473-4479.
29. Rummel MJ, von Gruenhagen U, Niederle N, et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with follicular, indolent and mantle cell lymphomas. Results of a randomized phase III study of the Study Group Indolent Lymphomas (StiL) [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112:900. Abstract 2596.